147 related articles for article (PubMed ID: 31701645)
1. The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
Park H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
Cancer Med; 2020 Jan; 9(1):43-51. PubMed ID: 31701645
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Park H; Bang JH; Nam AR; Eun Park J; Hua Jin M; Bang YJ; Oh DY
Sci Rep; 2019 Jul; 9(1):11131. PubMed ID: 31366979
[TBL] [Abstract][Full Text] [Related]
3. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
[No Abstract] [Full Text] [Related]
4. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
[TBL] [Abstract][Full Text] [Related]
5. Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?
Wang M; Zhu P; Chen Z; Yang L
Anticancer Drugs; 2022 Jan; 33(1):e686-e691. PubMed ID: 34459461
[TBL] [Abstract][Full Text] [Related]
6. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer.
Pacheco-Barcia V; Mondéjar Solís R; France T; Asselah J; Donnay O; Zogopoulos G; Bouganim N; Guo K; Rogado J; Martin E; Alcindor T; Colomer R
Pancreatology; 2020 Mar; 20(2):254-264. PubMed ID: 31866391
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy.
Batra A; Tang PA; Cheung WY
Am J Clin Oncol; 2021 Oct; 44(10):519-525. PubMed ID: 34366400
[TBL] [Abstract][Full Text] [Related]
8. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
9. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
Mizrahi JD; Rogers JE; Hess KR; Wolff RA; Varadhachary GR; Javle MM; Shroff RT; Ho L; Fogelman DR; Raghav KPS; Overman MJ; Pant S
Pancreatology; 2020 Apr; 20(3):501-504. PubMed ID: 31932214
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
[TBL] [Abstract][Full Text] [Related]
11. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of soluble transforming growth factor-β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer.
Kim JW; Lee KH; Kim JW; Suh KJ; Nam AR; Bang JH; Jin MH; Oh KS; Kim JM; Kim TY; Oh DY
Liver Int; 2021 Feb; 41(2):388-395. PubMed ID: 32780918
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
15. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
[TBL] [Abstract][Full Text] [Related]
16. Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis.
He C; Wang J; Zhang Y; Lin X; Li S
Pancreatology; 2020 Apr; 20(3):477-484. PubMed ID: 32131993
[TBL] [Abstract][Full Text] [Related]
17. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy.
Uemura S; Iwashita T; Ichikawa H; Iwasa Y; Mita N; Shiraki M; Shimizu M
Br J Nutr; 2021 May; 125(10):1140-1147. PubMed ID: 32883372
[TBL] [Abstract][Full Text] [Related]
18. Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.
Laurent-Badr Q; Barbe C; Brugel M; Hautefeuille V; Volet J; Grelet S; Desot E; Botsen D; Deguelte S; Pitta A; Abdelli N; Brasseur M; De Mestier L; Neuzillet C; Bouché O
Dig Liver Dis; 2020 Jun; 52(6):658-667. PubMed ID: 32362489
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
20. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Hohla F; Hopfinger G; Romeder F; Rinnerthaler G; Bezan A; Stättner S; Hauser-Kronberger C; Ulmer H; Greil R
Int J Oncol; 2014 Jan; 44(1):319-26. PubMed ID: 24247204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
